Drug recall · May 29, 2019
Losartan Potassium Tablets USP 25 mg recall
Why: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level at the manufacturer
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Losartan Potassium Tablets USP 25 mg 90 count bottle NDC 60429-316-90 Rx only GSMS Incorporated
- Lots / codes
GS015172 exp 06/2019 GS017634 02/2020, GS017653 exp 02/2020, GS017980 exp 02/2020, GS017276 exp 02/2020, GS017045 exp 02/2020,GS016726 exp 02/2020,
- Quantity
- 64,362 HDPE bottles
- Company
- Golden State Medical Supply Inc., Camarillo, CA
- Distribution
- IL, MI, MN, PA, TN, TX. Two (2) US government and one (1) Veterans Affairs accounts. No foreign accounts.
- Initiated
- May 1, 2019 · Voluntary: Firm initiated
- Classified
- May 19, 2019
- Reported
- May 29, 2019
- Ended
- February 25, 2020
- How notified
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Losartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.